Sanegene Bio
PrivateLast Round
Series B
Dec 8, 2025
Total Funding Raised
$228M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Sanegene Bio operates in Healthcare & Life Sciences and is based in Boston, Massachusetts. Its latest recorded funding round was a Series B round in December 2025.
Sanegene Bio is a biotechnology company that develops RNA interference (RNAi) therapeutics for obesity, cardiometabolic, and autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Sanegene Bio Comparables
Compare Sanegene Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Argo Biopharma | 90% | |
| Rona Therapeutics | 85% | |
| Vivatides Therapeutics | 84% |
For institutional investors. Book with your work email.
Sanegene Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Dec 8, 2025 | ||||
| Strategic | Nov 8, 2025 | ||||
| Series A Extension | Dec 1, 2023 | ||||
| Series A | Aug 31, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Sanegene Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Alwin Capital | Series A Extension, Series A |
| SymBiosis Capital Management | Series B |
| Lake Bleu Capital | Series B |
| Shanghai Healthcare Capital | Series A Extension |
| Oriza Holdings | Series B, Series A Extension, Series A |
| Hillhouse Investment | Series B, Series A |
| Tianjin TEDA Science and Technology Investment Co., Ltd. | Series A Extension |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors grew 297% MoM, reaching 4.6K.
- Aug 17, 2026
Grew 17% QoQ, from 29 to 34 employees.
For institutional investors. Book with your work email.
Sanegene Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Sanegene Bio's valuation, stock price, and market status.
Is Sanegene Bio a public or private company?
Sanegene Bio is a private company.
What is the current stock price of Sanegene Bio?
Sanegene Bio is a private company, so its shares have no public market price. Caplight tracks Sanegene Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Sanegene Bio worth (valuation)?
Valuation information for Sanegene Bio is not publicly available.
Can I buy Sanegene Bio stock?
Sanegene Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Sanegene Bio's last funding round?
Sanegene Bio's most recent funding round was Series B on December 8, 2025.
Who are the main investors in Sanegene Bio?
Key investors in Sanegene Bio include Hillhouse Investment.
Will Sanegene Bio IPO soon?
No public IPO plans have been announced for Sanegene Bio.
How can I track Sanegene Bio secondary market activity?
Caplight tracks bids, offers, and trades in Sanegene Bio's shares on secondary markets.